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Background: There is no standardised definition of a pulmonary exacerbation in cystic fibrosis (CF). In attempting to achieve standardised criteria
it is important to identify patient-reported indicators.
Methods: Interviews were undertaken with 47 adults with CF. Participants were asked to report symptoms experienced during a pulmonary
exacerbation in two ways: the first symptoms they become aware of, and how they subsequently recognised when they were improving.
Results: A range of systemic and respiratory symptoms were reported. Their relative importance varied by severity of disease. The severity and
subsequent improvement of an exacerbation was often described as limitations on their activities.
Conclusion: These preliminary data suggest that patient-reported indicators of a pulmonary exacerbation may not be the same for all adults with
CF. Whether different indicators are associated with specific demographic or clinical variables remains to be evaluated.
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In cystic fibrosis (CF) pulmonary exacerbations are a key
outcome measure of disease, clinical research and care. They are
associated with a poor health-related quality of life [1,2] disease
progression [3] and survival [4]. Despite the importance of
identifying a pulmonary exacerbation, there is no standardised
definition in CF and there is a lack of consensus among clinicians.
Standardised and valid criteria are important for an accurate
diagnosis of a pulmonary exacerbation, and the determination of
severity [5], so that (1) appropriate treatments can be initiated and
(2) a pulmonary exacerbation can be considered a meaningful
outcome measure in interventions.⁎ Corresponding author. Tel.: +44 1772 893790.
E-mail address: jabbott@uclan.ac.uk (J. Abbott).
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doi:10.1016/j.jcf.2009.07.003Recent reviews [6,7] have noted that three research groups
[8–10] have indicated that patient-reported symptoms were
more predictive of a pulmonary exacerbation than physical
examination and laboratory data and argue that diagnostic
criteria should focus on signs and symptoms. Scales that have
combined patient-reported signs and symptoms, clinical
evaluations and laboratory results have been developed for
clinical trials but their validity, reliability and sensitivity have
not been evaluated [11,12].
As part of the process of achieving standardised criteria it is
important to clearly identify patient-reported indicators of a
pulmonary exacerbation for different levels of disease severity.
This work aimed to identify the salient characteristics of a
pulmonary exacerbation as reported by adults with cystic
fibrosis, in order to contribute to the ongoing discussion on
defining a pulmonary exacerbation in CF disease.d by Elsevier B.V. All rights reserved.
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2.1. Sampling
Adults (age 16 years +) with cystic fibrosis were recruited
from two CF Centres in the UK. Purposive sampling ensured
representation of key variables including age, gender, in/out-
patient, small CF Unit/specialist CF Centre (treatingN50
patients), FEV1% predicted, BMI, microbiology, number of
clinically recorded exacerbations in past year, CF related
diabetes and nutritional and transplant status. Sixty people were
invited to take part in the study. All patients had previous
experience of pulmonary exacerbations but not all patients were
experiencing a PE at the time of interview. Those experiencing a
PE were interviewed towards the end of treatment. All
exacerbations had been diagnosed by a CF physician and
defined clinically as an increase in respiratory symptoms
(cough, volume and colour of sputum, or breathlessness)
associated with a fall in spirometry compared to usual values for
the patient. The study was approved by the North Staffordshire
Local Research Ethics Committee.
2.2. Interviews
Interviews were undertaken by a single researcher (A Holt).
Participants were asked to report symptoms experienced during
a pulmonary exacerbation in two ways: the first symptoms they
become aware of, and how they subsequently recognised when
they were improving. Voluntary reported symptoms were
elicited from the patients to encourage them to describe their
symptoms in their own words.
2.3. Conceptual approach and data analysis
A grounded theory approach utilizing constant comparative
analysis [13] was employed. The interview schedule was
amended as new concepts emerged from ongoing analysis to
ensure focused and appropriate questioning. Interviews were
taped, transcribed verbatim and the data analysed thematically.
Data collection and coding took place concurrently. Line by line
coding of the transcripts was undertaken. Codes were attachedTable 1
Characteristics of the sample (n=47).
Mild (FEV1 %N70) N=12 Moder
FEV1 % (range) 89.8 (72–105) 56.1 (4
Age (years, range) 24.0 (17–35) 27.2(1
BMI (range) 21.7(19.2–23.6) 21.9 (1
Recorded exacerbations in past year (range) 1.3 (0–3) 2.6 (0
Diabetes (n) 2 6
Enteral tube feeds (n) 1 1
Oral supplements (n) 2 8
Venous access device (n) 4 8
P. aeruginosa (n) 4 12
B. cepacia complex (n) 0 2
Inpatients (n) 3 6
Specialist CF Centre [treatingN50 patients] (n) 6 11
Mean FEV1, age, BMI and exacerbations and numbers of people with key variableto specific words, phrases, or sentences. These codes were then
grouped into conceptual categories [14,15]. This was done
independently by two researchers (JA, A Holt) and the coding
of concepts and categories agreed following discussions.
Descriptions of symptoms were investigated for different
disease severity groups: mild disease (FEV1N70%), moderate
disease (FEV1=40–70%) and severe disease (FEV1b40%).
3. Results
Forty-seven adults with cystic fibrosis agreed to be
interviewed. Thirteen people declined (lack of time/had to get
back to work=5; didn't want to talk about CF=5; no reason
given=3). The demographic and clinical characteristics of those
who declined were similar to those interviewed. The character-
istics of the sample are given in Table 1.
A range of systemic and respiratory symptoms were
experienced during a pulmonary exacerbation. Descriptions of
symptoms were similar regardless of whether or not the person
was being treated for an exacerbation at interview. There is
some evidence that the first symptoms patients became aware of
varied by severity of disease (Table 2). For many patients the
onset of an exacerbation was characterised by fatigue and
changes in sleep, cough, sputum, appetite, mood and daily
activities. Those with mild disease typically reported ‘cold’
symptoms whereas those with severe disease found it more
difficult to recognise the onset of an exacerbation. They
typically reported greater levels of fatigue (e.g., sleeping during
the day), greater effort required to cough and breathe, nausea/
vomiting (related to sputum/cough) and chest pain. For some
(especially those with severe disease) it was easier to describe
improvements in symptoms following treatment rather than
symptoms at the start of a pulmonary exacerbation. They often
did not realize how far they had deteriorated until they started to
notice an improvement.
There was more consistent reporting of symptoms across
severity groups when describing improvements from an
exacerbation. An improvement was primarily described in
terms of the activities they were able to perform (e.g., return to
work, shopping) followed by improvements in fatigue, sleep,
sputum, cough and mood (Table 3). Those with severe diseaseate (FEV1 % 40–69) N=18 Severe (FEV1 %b40) N=17 All patients N=47
1–68) 29.7 (15–39) 54.5 (15–105)
7–47) 26.9 (19–34) 26.8 (17–47)
8.1–29.3) 19.0 (14.4–22.7) 21.0 (14.4–29.3)
–6) 3.5 (0–9) 2.6 (0–9)
11 19
8 10
10 20
14 26
17 33
2 4
16 25
14 31
s for each disease severity group.
Table 2
First patient-reported symptoms of a pulmonary exacerbation (most common phrases patients used to describe symptoms).
Mild (FEV1 % predictedN70) Moderate (FEV1 % predicted 40–69) Severe (FEV1 % predictedb40)
Most report (over 80% sample) Most report (over 80% sample) Most report (over 80% sample)
Tiredness, disturbed sleep at night Fatigue, disturbed sleep at night Fatigue, sleep in day, disturbed sleep at night (due to cough)
Increased cough Increased cough Increased cough, more effort to cough, hurts to cough (chest pain)
Sputum (thicker, darker) Increased sputum (thicker, darker) Increased sputum (thicker, darker, tastes nasty), more difficult
to cough up
Nausea/vomiting (related to sputum/coughing)
Decreased appetite Decreased appetite
Miserable Miserable
Less energetic Decreased activities
Feel unwell, general aches, cold symptoms,
runny nose, sore throat
Breathless: at rest/light activities, more effort to breath
Many report (over 50% sample) Many report (over 50% sample)
Decrease appetite Decreased activities
Decreased concentration Breathless with activities, difficulty breathing at night
General body aches, chest aches/pain
Decreased weight
Less frequently reported Less frequently reported Less frequently reported
Decreased weight Sleep in daytime Decreased weight
Breathlessness Nausea/vomiting (related to sputum/coughing) Decreased concentration
Headaches, general body aches, chest ache/pain Headaches, general aches and pains
Cold symptoms sore throat Runny nose
Lose interest in appearance
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coughing and breathing.
4. Discussion
In this sample, patient-reported indicators of a pulmonary
exacerbation differ according to the severity of CF disease. The
clearest differences are between the mild and severe diseaseTable 3
Patient-reported symptoms of improvement from a pulmonary exacerbation (most c
Mild (FEV1 % predictedN70) Moderate (FEV1 % predicted 40–
Most report (over 80% sample) Most report (over 80% sample)
More energetic (able to do activities) Able to do more activities (in part
able to go back to work/education
Less tired Less fatigue
Better sleep Better sleep
Less sputum, easier to cough up
(thinner, lighter colour)
Less sputum, easier to cough up
(thinner, lighter colour)
Decreased cough in day and night Decreased cough in day and night
Happier Happier
Easier to breath Improved appetite
Less frequently reported Less frequently reported
Improved appetite Easier to breath
Improved weight
Improved concentration
Less headaches
Less chest ache/pain
Less stress incontinencecategories. Indicators of a pulmonary exacerbation in the
moderate disease group may be confused as the group consists
of those who may have an FEV1% predicted of just over 40%
and those with an FEV1 of almost 70% predicted. The most
common phrases used by adults with CF to describe their
symptoms create apparent anomalies. Those with mild disease
commonly talked about feeling tired whereas those with more
advanced disease commonly used the word fatigue. This mayommon phrases patients used to describe symptoms).
69) Severe (FEV1 % predictedb40)
Most report (over 80% sample)
icular,
)
Able to do more activities (e.g., go for a walk, shopping,
able to use exercise bike)
Less fatigue
Better sleep
Less sputum, easier to cough up (thinner,
lighter colour, better taste)
Decreased cough, less effort to cough, less painful to cough
Happier
Less breathless, less effort to breathe, hurts less to breathe
Many report (over 50% sample)
Improved appetite
Improved weight
Improved concentration
Less headaches
Less aches and pains
Less nausea/vomiting
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Additionally, patients perceived coughing or breathlessness and
the amount of effort required to cough or breathe as different
concepts. These are preliminary data from a carefully selected
sample but whether all patients make these distinctions remains
to be evaluated. Further qualitative work and larger samples
employing quantitative methods are required to further explore
these results. Identifying and understanding the patient's
phraseology is important if reliable and valid standardised
criteria are to be developed. Whether different indicators are
associated with specific demographic or clinical variables (e.g.
diabetes, B. cepacia complex) also remains to be evaluated.
Furthermore, the important diagnostic characteristics of a
pulmonary exacerbation have been shown to differ between
paediatricians and physicians [8] indicating a need to ascertain
the views of children and examine whether their descriptions of
a pulmonary exacerbation map onto these results from adults.
Exacerbations of pulmonary symptoms need to be recog-
nised by the patient and diagnosed by the clinician as early as
possible. There is suggestive evidence that there are differences
in patient descriptions of initial symptoms reported by those
with mild and severe disease as categorised by FEV1. As reports
of improvements were more consistent across disease severity
groups it may be easier to develop criteria to monitor changes
following interventions. It is interesting to note that when
people with CF are asked to identify the initial symptoms of a
pulmonary exacerbation they tend to focus on how they feel.
When asked how they recognise when they were improving the
focus shifts to what they are able to do. This is noteworthy given
that patient-reported physical functioning has been shown to
predict survival [16]. The importance of qualitative work is
often undervalued but it is essential to generate accurate patient-
reported information. These data have implications for devel-
oping standardised and valid criteria of a pulmonary exacerba-
tion and the development of patient-reported tools. The
methodological challenge for the development of such scales
is that they need to be sensitive to these issues.References
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